Is your organization missing from this list? Reach out to Danielle Cann, Strategic Alliance Partnership Coordinator, to learn more about the complimentary strategic partnership program: dcann@mjhlifesciences.com
Blinatumomab-Linked ICANS Cases Higher Than Previously Reported
Daratumumab Decreased Progression Risk in High-Risk Smoldering MM
Risk Factors Determine Symptom Burden Profiles by Age Group
Study Findings Support D-VRd for Transplant-Ineligible or -Deferred MM